Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials

Authors:
Open Access
Publisher website
Google Scholar
Abstract
No abstract available
Funding Information
  • Johnson and Johnson
  • National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (NIHR203308)

This publication has 36 references indexed in Scilit: